Table 3.
Characteristics of medication application by allocated clusters.
| All | SIDD | SIRD | MOD | MARD | P value | |
|---|---|---|---|---|---|---|
| Medication, N (%) | 486 (100) | 75 (15) | 106 (22) | 109 (22) | 196 (40) | – |
| Metformin, N (%) | 362 (74) | 54 (72) | 78 (74) | 94 (86) | 136 (69) | 0.012 |
| SU, N (%) | 60 (12) | 9 (12) | 15 (14) | 12 (11) | 24 (12) | 0.917 |
| TZDs, N (%) | 15 (3) | 1 (1) | 5 (5) | 6 (6) | 3 (2) | 0.139 |
| AGI,N (%) | 223 (46) | 43 (57) | 40 (38) | 40 (37) | 100 (51) | 0.006 |
| DPP-4,N (%) | 270 (56) | 37 (49) | 53 (50) | 54 (50) | 126 (64) | 0.017 |
| SGLT-2,N (%) | 84 (17) | 10 (13) | 18 (17) | 21 (19) | 35 (18) | 0.760 |
| GLP-1,N (%) | 24 (5) | 1 (1) | 4 (4) | 17 (16) | 2 (1) | <0.001 |
| Glinides, N (%) | 21(4) | 3 (4) | 8 (8) | 5 (5) | 5 (3) | 0.239 |
| Insulin, N (%) | 192 (40) | 57 (76) | 21 (20) | 49 (50) | 65 (33) | <0.001 |
| Statins, N (%) | 326 (67) | 61 (81) | 62 (59) | 78 (72) | 125 (64) | 0.006 |
| AHT, N (%) | 195 (40) | 34 (45) | 51 (48) | 39 (36) | 71 (36) | 0.124 |
All values were N (%). SU, sulphonylurea; TZDs, thiazolidinediones; AGI, α-glucosidase inhibitor; DPP4-I, dipeptidyl peptidase 4 inhibitors; SGLT2, sodium-glucose co-transporter 2 inhibitors; GLP-1, glucagon-like peptide-1; AHT, antihypertensive treatment (includes diuretics, β-blockers, and renin–angiotensin system inhibitors); SIDD, severe insulin-deficient diabetes; SIRD, severe insulin-resistant diabetes; MOD, mild obesity-related diabetes; MARD, mild age-related diabetes.